Premium
Myocardial regeneration with bone‐marrow‐derived stem cells
Author(s) -
Yoon YoungSup,
Lee Namho,
Scadova Heather
Publication year - 2005
Publication title -
biology of the cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.543
H-Index - 85
eISSN - 1768-322X
pISSN - 0248-4900
DOI - 10.1042/bc20040099
Subject(s) - stem cell , biology , regeneration (biology) , progenitor cell , stem cell transplantation for articular cartilage repair , myocardial infarction , bone marrow , transplantation , adult stem cell , clinical uses of mesenchymal stem cells , cancer research , microbiology and biotechnology , endothelial stem cell , embryonic stem cell , immunology , pathology , medicine , biochemistry , in vitro , gene
Despite significant therapeutic advances, heart failure remains the predominant cause of mortality in the Western world. Ischaemic cardiomyopathy and myocardial infarction are typified by the irreversible loss of cardiac muscle (cardiomyocytes) and vasculature composed of endothelial cells and smooth muscle cells, which are essential for maintaining cardiac integrity and function. The recent identification of adult and embryonic stem cells has triggered attempts to directly repopulate these tissues by stem cell transplantation as a novel therapeutic option. Reports describing provocative and hopeful examples of myocardial regeneration with adult bone‐marrow‐derived stem and progenitor cells have increased the enthusiasm for the use of these cells, yet many questions remain regarding their therapeutic potential and the mechanisms responsible for the observed therapeutic effects. In this review article we discuss the current preclinical and clinical advances in bone‐marrow‐derived stem or progenitor cell therapies for regeneration or repair of the ischaemic myocardium and their multiple related mechanisms involved in myocardial repair and regeneration.